DB01178 - Chlormezanone
| Identification | |
|---|---|
| Name | Chlormezanone |
| Accession Number | DB01178 (APRD00865) |
| Type | small molecule |
| Description | A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. [PubChem] |
| Structure |
|
| Categories (*) | |
| Molecular Weight | 273.736 |
| Groups | approved |
| Monoisotopic Weight | 273.022641652 |
| Pharmacology | |
| Indication | Used in the management of anxiety and in the treatment of muscle spasm. |
| Mechanism of action | Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways. |
| Absorption | Not Available |
| Protein binding | Not Available |
| Biotransformation | Not Available |
| Route of elimination | Not Available |
| Toxicity | Symptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death. |
| Affected organisms |
|
| Interactions | |
| Drug Interactions | Not Available |
| Food Interactions | Not Available |
Targets
| Translocator protein | |
|---|---|
| Name | Translocator protein |
| Gene Name | TSPO |
| Pharmacological action | yes |
| Actions | agonist |
| References |
|
| DTHybrid score | 0.2259 |